Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

A3B5 can reduce skin pigmentation and slow melanoma growth.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.